参考文献/References:
[1] Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis[J]. JAMA,2007,298(2):194-206.
[2] Buse JB, Henry RR, Han J,et al. Effects of exenatide(exendin-4)on glycemic control over 30 weeks in sulfonylurea-treatedpatients with type 2 diabetes[J]. Diabetes Care, 2004,27(11):2628-2635.
[3] Moretto TJ, Milton DR, Ridge TD,et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naivepatients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-groupstudy[J].Clin Ther,2008,30(8):1448-1460. DOI: 10.1016/j.clinthera.2008.08.006.
[4] Liutkus J, Rosas Guzman J, Norwood P,et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or incombination with metformin[J].Diabetes Obes Metab,2010,12(12):1058-1065. DOI: 10.1111/j.1463-1326.2010.01251.x.
[5] Kendall DM, Riddle MC, Rosenstock J,et al. Effects of exenatide(exendin-4)on glycemic control over 30 weeks in patients with type 2diabetes treated with metformin and a sulfonylurea[J].Diabetes Care,2005,28(5):1083-1091.
[6] Vilsboll T, Zdravkovic M, Le-Thi T,et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes[J].Diabetes Care,2007,30(6):1608-1610.
[7] Buse JB, Rosenstock J, Sesti G,et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial(LEAD-6)[J].Lancet,2009,374(9683):39-47.DOI: 10.1016/S0140-6736(09)60659-0.
[8] Marre M, Shaw J, Brändle M,et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks producesgreater improvements in glycaemic and weight control compared with adding rosiglitazone orplacebo in subjects with type 2 diabetes(LEAD-1 SU)[J]. Diabet Med,2009,26(3):268-278. DOI: 10.1111/j.1464-5491.2009.02666.x.
[9] Astrup A, Carraro R, Finer N,et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1analog, liraglutide[J].Int J Obes(Lond),2012,36(6):843-854. DOI: 10.1038/ijo.2011.158.
[10] Aschner P, Kipnes MS, Lunceford JK,et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes[J].Diabetes Care,2006,29(12):2632-2637.
[11] Bergenstal RM, Wysham C, Macconell L,et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunctto metformin for treatment of type 2 diabetes(DURATION-2): a randomised trial[J].Lancet,2010,376(9739):431-439. DOI: 10.1016/S0140-6736(10)60590-9.
[12] Pratley RE, Nauck M, Bailey T,et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial[J].Lancet,2010,375(9724):1447-1456. DOI: 10.1016/S0140-6736(10)60307-8.
[13] Hermansen K, Kipnes M, Luo E,et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin[J].Diabetes Obes Metab,2007,9(5):733-745.
[14] Kikuchi M, Abe N, Kato M,et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2009,83(2):233-240. DOI: 10.1016/j.diabres.2008.10.006.
[15] Rosenstock J, Baron MA, Dejager S,et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial[J].Diabetes Care,2007,30(2):217-223.
[16] Ferrannini E, Fonseca V, Zinman B,et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy[J].Diabetes Obes Metab,2009,11(2):157-166. DOI: 10.1111/j.1463-1326.2008.00994.x.
[17] Hollander PL, Li J, Frederich R,et al. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus[J].Diab Vasc Dis Res,2011,8(2):125-135. DOI: 10.1177/1479164111404575.
[18] DeFronzo RA, Hissa MN, Garber AJ,et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone[J].Diabetes Care,2009,32(9):1649-1655. DOI: 10.2337/dc08-1984.
[19] Chacra AR, Tan GH, Apanovitch A,et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial[J].Int J Clin Pract,2009,63(9):1395-1406. DOI: 10.1111/j.1742-1241.2009.02143.x.
[20] Moses RG, Kalra S, Brook D,et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea[J].Diabetes Obes Metab,2014,16(5):443-450. DOI: 10.1111/dom.12234.
[21] Taskinen MR, Rosenstock J, Tamminen I,et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study[J].Diabetes Obes Metab,2011,13(1):65-74. DOI: 10.1111/j.1463-1326.2010.01326.x.
[22] Owens DR, Swallow R, Dugi KA,et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study[J].Diabet Med,2011,28(11):1352-1361. DOI: 10.1111/j.1464-5491.2011.03387.x.
[23] Gomis R, Espadero RM, Jones R,et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study[J].Diabetes Obes Metab,2011,13(7):653-661. DOI: 10.1111/j.1463-1326.2011.01391.x.
[24] Yki-Järvinen H, Rosenstock J, Durán-Garcia S,et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a≥52-week randomized, double-blind study[J].Diabetes Care,2013,36(12):3875-3881. DOI: 10.2337/dc12-2718.
相似文献/References:
[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(03):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(03):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]